Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tinnitus 1Ototoxicity 1Lung Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Deafness 1

Interventions

pembrolizumab 88Carboplatin 77Specimen Handling 76Magnetic Resonance Spectroscopy 63Pemetrexed 59Cisplatin 47durvalumab 44Paclitaxel 38Nivolumab 34atezolizumab 32osimertinib 29Radiotherapy 29Radiosurgery 29Biopsy 26Blood Specimen Collection 25Gemcitabine 24Docetaxel 24Immunoglobulin G 23Disulfides 22Standard of Care 21Drug Therapy 21Etoposide 19Taxes 18Practice Guidelines as Topic 18Radiation 17Educational Status 16130-nm albumin-bound paclitaxel 15X-Rays 14Surveys and Questionnaires 14Bevacizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × ebselen × 1 year × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡